Integriculture adds Niigata VC backing, months after seven-investor raise
What's the deal? Japanese cellular agriculture startup Integriculture has closed an undisclosed venture round from Niigata Venture CapitalDealroom has a profile for this one. Try Dealroom →, drawn from its Regional Revitalisation Niigata No. 2 Fund. The Tokyo-based company develops a "cellular agriculture infrastructure platform" to produce cosmetics ingredients, cell-based foods, and materials from cultured cells.
Why now? The investment comes just months after Integriculture completed a July raise from seven domestic and overseas VCs and corporates. The new, smaller injection extends that momentum rather than marking a major financing event.
What's the endgame? Integriculture plans to accelerate product development in cosmetics ingredients, expand sales of its cellular agriculture infrastructure, and strengthen in-house research. It is also building a Niigata base to test and commercialise its technology using local resources such as sake lees.
What's new about the Niigata angle? The deal ties the company to a regional food-tech cluster, working with local firms including Ichimasa KamabokoDealroom has a profile for this one. Try Dealroom → and Tsunan Jozo. Chief executive officer Yuki Hanyu said a "food-tech industry cluster" including cell-based food has "begun in earnest" in Niigata (translated from Japanese).
What could go wrong? Integriculture's larger milestones lie ahead: production-process validation in Singapore via a partnership with Sumitomo Riko, and an approval application for cell-based food targeted within 2026. Public information does not reveal whether this round is large enough to determine those outcomes.
The signal: The raise reflects how regional funds and local partners are backing cultured-protein ventures as food security and alternative protein gain policy support in Japan. For Integriculture, Niigata's brewing and fermentation base — where cells can grow in brewing water and sake lees — offers a model it hopes to replicate nationwide and abroad.
Read more: prtimes.jp
Image credit: Generated with Gemini
